According to a recent LinkedIn post from Xeltis, the company participated in the 29th European Vascular Course in Maastricht, where its aXess vascular access conduit featured in multiple clinical presentations. Speakers discussed arteriovenous grafts, bioabsorbable graft technology, and cannulation innovations, with aXess used as a reference case.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Xeltis staff engaged attendees at a dedicated booth to discuss its regenerative vascular access conduits and ongoing pivotal trials for aXess in the E.U. and U.S. This visibility among vascular access specialists, combined with trial progress and proximity to potential commercialization, suggests Xeltis is positioning aXess for future market entry, which could be a key driver of long‑term revenue and competitive differentiation in dialysis vascular access.